QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs ALT 803 (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms QUILT-3.055
- Sponsors Altor BioScience Corporation
- 25 Jun 2018 Planned initiation date changed from 1 Jan 2018 to 1 Jun 2018.
- 18 May 2018 Planned End Date changed from 1 Apr 2022 to 1 Aug 2022.
- 18 May 2018 Planned primary completion date changed from 1 Jan 2021 to 1 May 2021.